In the BE RADIANT phase 3b trial, bimekizumab provided greater and durable improvements in patient-reported symptoms, skin clearance, and quality of life over 3 years compared with secukinumab in moderate to severe plaque psoriasis. At week 4, significantly more patients on bimekizumab achieved complete absence of itching, skin pain, and scaling. The benefits were sustained through 3 years, including after patients switched from secukinumab.
A phase IIb trial demonstrated that low-dose IL-2 therapy produced dose-dependent improvements in SLE patients, with 69.7% achieving SRI-4 response at the highest dose versus 23.5% on placebo. A separate systematic review found IL-17 inhibitors remain potential SLE treatment options, though efficacy data are limited.
Recent research highlights advances in precision medicine for psoriatic arthritis, including a biopsy-driven treatment strategy that improved clinical outcomes and ongoing investigation into new biologic agents, combinations, and biomarker panels.
